l e t t e r s
The main familial focal epilepsies are autosomal dominant nocturnal frontal lobe epilepsy, familial temporal lobe epilepsy and familial focal epilepsy with variable foci. A frameshift mutation in the DEPDC5 gene (encoding DEP domain-containing protein 5) was identified in a family with focal epilepsy with variable foci by linkage analysis and exome sequencing. Subsequent pyrosequencing of DEPDC5 in a cohort of 15 additional families with focal epilepsies identified 4 nonsense mutations and 1 missense mutation. Our findings provided evidence of frequent (37%) loss-offunction mutations in DEPDC5 associated with a broad spectrum of focal epilepsies. The implication of a DEP (Dishevelled, Egl-10 and Pleckstrin) domain-containing protein that may be involved in membrane trafficking and/or G protein signaling opens new avenues for research.
Epilepsy is a frequent neurological disorder characterized by spontaneous, recurrent seizures. Focal epileptic seizures are thought to originate within networks limited to one hemisphere. Several autosomal dominant, non-lesional focal epilepsies have been described as specific age-related and electroclinical syndromes: autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE; MIM 600513) 1 , familial temporal lobe epilepsy (FTLE; MIM 600512) 2 , including mesial and lateral forms (also termed autosomal dominant epilepsy with auditory features (ADEAF; MIM 604619) 3 , and familial focal epilepsy with variable foci (FFEVF; MIM 604364), characterized by focal seizures that are initiated in distinct cortical regions in different family members 4 . The only gene mutations currently identified are those linked to ADNFLE (CHRNA4, CHRNA2, CHRNB2 and KCNT1, encoding, respectively, the α4, α2 and β2 subunits of the neuronal nicotinic acetylcholine receptor and a potassium channel subunit) 5, 6 and to ADEAF (LGI1, encoding epitempin) 7 . Although no causal genes have yet been identified for FFEVF, linkage to 22q12 has been reported in several families 4, [8] [9] [10] [11] .
We have previously described the electroclinical characteristics of 19 families with autosomal dominant focal epilepsies, subdivided into ADNFLE, FTLE and FFEVF 12 . Two large multiplex French families (N and S) with diagnosed FFEVF were selected from this cohort for linkage analysis using a high-density genome-wide scan with 10,000 SNPs. Both families mapped to the FFEVF-associated locus on chromosome 22q12, with maximum logarithm of odds (LOD) scores of 2.08 (family N) and 1.81 (family S). Haplotype reconstruction confirmed the segregation of a disease haplotype in both families ( Supplementary  Figs. 1 and 2) .
We then sequenced the entire exome of subjects N-III:4 and N-III:6 and sought rare coding variants in the 22q12 candidate region. In both individuals, we found the same single-base deletion, c.1122delA, in exon 16 of the DEPDC5 gene (also known as KIAA0645; NM_001242896). This variant caused a frameshift, p.Leu374Phefs*30, introducing a premature stop codon 29 amino acids downstream. The c.1122delA variant fully segregated with the phenotype within the family (Fig. 1) .
We next sought DEPDC5 mutations in 15 additional probands from the families with autosomal dominant focal epilepsies (ADNFLE, n = 7; FTLE, n = 4; FFEVF, n = 4) 12 , including family S in which disease was linked to the 22q12 locus. Massively parallel pyrosequencing screening of all 43 exons and splice regions of DEPDC5 identified 4 further nonsense mutations (encoding p.Arg239* in family S, p.Arg328* in family L, p.Gln372* in family Q and p.Gln1523* in family B) and 1 missense mutation (p.Arg485Gln in family O) in 5 families (Fig. 2a, Table 1 and Supplementary Fig. 3 ). All mutations were shown to segregate with the phenotype within the families, except for the mutation encoding p.Gln1523* in family B, where additional family members were unavailable for analysis (Fig. 1) . In family Mutations of DEPDC5 cause autosomal dominant focal epilepsies l e t t e r s O, the father (O-II:8) may have transmitted the mutation encoding p.Arg485Gln, as it was not inherited from the mother (O-II:7). The arginine at position 485 is a highly conserved amino acid (Fig. 2b) . Different prediction software tools-MutationTaster, SIFT and PolyPhen-2-predicted that the arginine-to-glutamine alteration at position 485 is disease causing, tolerated and possibly damaging, respectively. This p.Arg485Gln substitution was not detected in a cohort of 450 controls of matched ancestry. None of the six DEPDC5 variants was present in dbSNP135 or the 1000 Genomes Project database or in the 6,503 exomes for which variants are currently listed in the National Heart, Lung, and Blood Institute (NHLBI) exome variant server (EVS) database. One nonsense mutation (1/11,813) and 1 frameshift mutation (1/11,775) have been identified in the 6,503 exomes listed in the EVS database, and no copy number variations disrupting the DEPDC5 coding sequence have been reported in the Database of Genomic Variants. DEPDC5 mutations occurred significantly more often in our group of affected individuals (5/32; P = 5 × 10 −12 , Fisher exact test).
Four out of six mutations (encoding p.Arg239*, p.Arg328*, p.Gln372* and p.Leu374Phefs*30 alterations) are predicted to result in degradation of the mutated transcript by the nonsense-mediated mRNA decay (NMD) system, whereas the nonsense mutation encoding p.Gln1523*, located in the last exon of the gene, is not likely to be targeted by the NMD system. To confirm that the mutation encoding the p.Arg239* alteration leads to NMD, we treated cultured lymphoblasts from three mutation carriers (S-III:10, S-IV:7 and S-IV:9) and one spouse (S-III:11) with emetine, an NMD inhibitor. With sequencing of DEPDC5 cDNA the mutation encoding p.Arg239* was only detected when NMD was inhibited ( Fig. 2c) , showing that this nonsense mutation specifically leads to transcript degradation. DEPDC5 haploinsufficiency is likely to be the cause of disease in individuals carrying this mutation.
We identified mutations in one-third of the families in our cohort (6/16, 37%), and, overall, 20 subjects with epilepsy carried a DEPDC5 mutation. The age of disease onset ranged from 0 to 39 years (mean of 12.9 ± 10.9 (s.d.)). DEPDC5 mutations were not limited to families with the FFEVF phenotype but were also found in a family with two individuals exhibiting a typical nocturnal frontal lobe epilepsy (family B) 13 2) carried the mutations. Our data strongly support the causal role of DEPDC5 in a subset of our families with focal epilepsies. However, the observed low penetrance and variable expressivity (in age at onset and localization of seizure focus in various brain areas) suggest that other gene(s) or epigenetic and environmental factors modulate the phenotype.
Because five out of the six mutations introduce a premature stop mutation, loss of function of DEPDC5 presumably causes the epileptic phenotype. It will now be crucial to determine the function of the DEPDC5 gene product and examine how its loss causes epilepsy. DEPDC5 transcript was first identified in human brain cDNA libraries 15 . This gene is strongly expressed at rather constant levels npg l e t t e r s in both the developing and adult human brain (Human Brain Transcriptome), consistent with a role in epilepsy. We attempted to obtain clues from sequence analysis and database mining. The RefSeq collection reports five putative isoforms of DEPDC5 of 1,572, 559, 1,594, 1,603 and 1,503 amino acids in length for isoforms 1-5, respectively. One of the mutations (encoding p.Gln1523*) lies within an exon absent from isoform 2, suggesting that this isoform is not involved in pathology. Alignment with orthologs, using reciprocal best-BLASTP hits, and phylogeny showed that the DEPDC5 protein is highly conserved in metazoa and fungi (but absent from plants) ( Supplementary  Fig. 4) , indicating a core role for this ancient eukaryotic factor. We note also that DEPDC5 and its orthologs occur as single gene copies, even within genomes known to be ancient polyploids, such as Dario rerio and Saccharomyces cerevisiae. This evidence, together with the dominance of epilepsy-causing mutations, suggests that gene dosage may be critical for normal brain function. Transmembrane prediction using hidden Markov model (TMHMM) analysis also showed that the DEPDC5 protein has no transmembrane domain and no homology with known ion channels. The presence of a DEP domain, a globular protein motif of about 80 amino acids found in many proteins involved in G protein signaling pathways, suggests that DEPDC5 may be a G protein substrate. The DEPC5 ortholog gene product in yeast, Yjr138p (also known as SEA1), is part of an evolutionary conserved multiprotein SEA complex involved in membrane trafficking 16 . DEPDC5 may also be involved in oncological processes, as (i) it was reported to be deleted in two glioblastomas 17 and (ii) an intronic SNP (rs1012068) in the DEPDC5 locus has been associated with hepatocellular carcinoma risk 18 .
In conclusion, this work provides clear evidence that loss-of-function mutations in DEPDC5 are a major cause in a broad spectrum of autosomal dominant focal epilepsies. It shows that a single gene, DEPDC5, is a common genetic actor in epileptic syndromes with different brain localization and electroclinical expression, including ADNFLE, FTLE and FFEVF. Thus, seizure initiation sites may be dissociated from underlying genetic mechanisms, in striking contrast to previous data, which link LGI1 mutations with a seizure focus localized in the lateral temporal lobe and mutations in nicotinic acetylcholine subunit genes with a seizure focus localized in the frontal lobe. Understanding the relationship between loss of DEPDC5 function and the genesis of pathological neuronal synchronies in different epileptic networks and syndromes will provide new, clinically relevant insights and knowledge that may be useful in genetic counseling. With no known homology between the DEPDC5 protein and other proteins, new pathogenic mechanisms seem likely. DEPDC5 is the second gene after LGI1 found to be mutated in familial focal epilepsies not encoding ion channel or transmitter receptor subunits. In addition to channelopathies, we must consider alternative genetic pathways leading to epileptogenesis. 
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METhODS
Methods and any associated references are available in the online version of the paper.
ONLINE METhODS
Families and subjects. Sixteen unrelated families from western Europe with non-lesional focal epilepsies were studied 12 Bioinformatics analysis. Bioinformatics analysis of sequencing data was based on the Illumina pipeline (CASAVA 1.8). CASAVA aligns reads to the human reference genome (hg19) with the alignment algorithm ELANDv2 (it performs multiseed and gapped alignments), calls SNPs on the basis of allele calls and read depth, and detects variants (SNPs and indels). Only positions included in the bait coordinates were conserved. Genetic variation was annotated with the IntegraGen in-house pipeline, consisting of gene annotation (using RefSeq), detection of known polymorphisms (using dbSNP135 and the 1000 Genomes Project database) and characterization of mutations as exonic, intronic, silent or nonsense.
Screening of a cohort by pyrosequencing. All 43 exons and intron-exon junctions of DEPDC5 (except exon 2, which was screened by Sanger sequencing) were analyzed by universal tailed amplicon sequencing (454 Sequencing Technology, Roche). This approach used the 454 GS Junior system and involved an initial PCR amplification with primer sets designed to amplify exons corresponding to the sequence under accession NM_001242896 (Supplementary Table 1 ), a second PCR aiming to incorporate multiplex identifier and 454 adaptors and, finally, an emulsion PCR step carried out according to the emPCR Amplification Method Manual (Roche).
Validation of exome and pyrosequencing variants by Sanger sequencing.
Mutations found through exome sequencing and pyrosequencing were validated by Sanger sequencing using the BigDye Terminator kit on an ABI Prism 3730 DNA Analyzer (Applied Biosystems). Segregation analysis of withinfamily variants was carried out using the same primers as for pyrosequencing (Supplementary Table 1 ). Mutation interpretation was assessed with Alamut version 2.2 (Interactive Biosoftware). The effects of amino-acid substitutions on protein function were predicted using MutationTaster, SIFT and PolyPhen-2.
Cell culture and mRNA experiments. Lymphoblastic cells from three mutation carriers (S-III:10, S-IV:7 and S-IV:9) and one spouse (S-III:11) from family S were treated (or not) overnight with 10 mg/ml emetine to inhibit NMD. Total RNA was extracted with the Qiagen RNeasy Mini kit and reverse transcribed with the ThermoScript RT-PCR System (Invitrogen). DEPDC5 cDNA was amplified and sequenced using specific primers located in exons 12 and 15.
Phylogenetic tree reconstruction. All amino-acid sequences encoded by orthologous genes were retrieved from NCBI and aligned using MUSCLE. Visual inspection of the alignment with SEAVIEW showed that homology was present across several regions of the protein. Protein alignment was trimmed to 454 homologous sites using GBLOCK. Tree reconstruction was performed by maximum likelihood using PhyML software with an LG matrix.
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